Capitol Hill Kennedy announces massive cuts, centralization at HHS—NCI and FDA hitAlso this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology March 28, 2025Vol.51 No.12By Claire Marie Porter and Jacquelyn Cobb
Drugs & Targets FDA approves cabozantinib for patients 12 and up with pNET and epNET March 28, 2025Vol.51 No.12
Drugs & Targets FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) March 21, 2025Vol.51 No.11
Drugs & Targets FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer March 14, 2025Vol.51 No.10
Clinical Roundup CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study March 07, 2025Vol.51 No.09
Clinical Roundup Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera March 07, 2025Vol.51 No.09
Guest Editorial Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology February 28, 2025Vol.51 No.08By Harpreet Singh
In Brief Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president February 28, 2025Vol.51 No.08
